NCT03046901 is a NA clinical trial of Vancomycin in Primary Sclerosing Cholangitis, sponsored by Ochsner Health System.

Who is sponsoring NCT03046901?

NCT03046901 is sponsored by Ochsner Health System.

What drugs are being tested in NCT03046901?

Interventions in NCT03046901: Vancomycin.

What condition does NCT03046901 study?

NCT03046901 studies Primary Sclerosing Cholangitis, Post- Orthotopic Liver Transplantation.

Is NCT03046901 still recruiting?

NCT03046901 is currently withdrawn. Last updated 29 March 2019.

Last reviewed 2019-03-29 · How we verify

NCT03046901

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients

Withdrawn NA Last updated 29 March 2019

What this trial tests

NA trial testing Vancomycin in Primary Sclerosing Cholangitis. Withdrawn.

Timeline

7 December 2016

Primary endpoint
25 February 2019

25 February 2019

Quick facts

Lead sponsor	Ochsner Health System
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Start date	7 December 2016
Primary completion	25 February 2019
Estimated completion	25 February 2019
Sites	1 location across United States

Drugs / interventions tested

Vancomycin (vancomycin) — full drug profile →

Conditions studied

Primary Sclerosing Cholangitis — all drugs for Primary Sclerosing Cholangitis →
Post- Orthotopic Liver Transplantation — all drugs for Post- Orthotopic Liver Transplantation →

Sponsor

Ochsner Health System — full company profile →

Who can join

Eligibility, any sex, with Primary Sclerosing Cholangitis or Post- Orthotopic Liver Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to investigate the safety and efficacy of oral vancomycin in patients with recurrent Primary Sclerosing Cholangitis (PSC) after liver transplantation. The primary endpoint is looking at the effect of the drug on liver function tests, an important surrogate of PSC disease activity at 12 weeks on treatment. Secondary endpoints include a decrease in liver function tests at 1 year, changes in bilirubin and adverse events. Effective treatment at the onset of PSC recurrence may lead to decreases in disease progression, recurrent liver failure, and repeat liver transplantation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Network proximity analysis as a theoretical model for identifying potential novel therapies in primary sclerosing cholangitis.
Leighton J, Jones DEJ, Dyson JK, Cordell HJ. · · 2024 · PMID 38862968 · DOI 10.1186/s12920-024-01927-2

Verify or expand the search:

Other trials of Vancomycin

Trials testing the same drug.

NCT07435051 — Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cie · Phase 3 · not yet recruiting
NCT06567808 — Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over Trial · Phase 4 · not yet recruiting
NCT06702345 — Clostridioides Difficile Controlled Human Infection Model · NA · not yet recruiting
NCT06716749 — Effectiveness of Adding Morphine to Intraosseous Vancomycin for Pain Control in Total Knee Arthroplasty · Phase 2 · completed
NCT06439953 — Irrisept Solution for Instrumented Spine Surgery · NA · recruiting

Other recruiting trials for Primary Sclerosing Cholangitis

Currently open trials in the same condition.

NCT07229911 — A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC) · Phase 1 · recruiting
NCT06905054 — Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation · Phase 2 · recruiting
NCT06455280 — A Study of SIPLIZUMAB in AILD and LT Patients · Phase 1 · recruiting
NCT06519162 — Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome · recruiting
NCT06351696 — The Effects of Bromelain Supplement in Patients With Ulcerative Colitis · NA · recruiting

Other Ochsner Health System trials

Trials by the same sponsor.

NCT07516327 — Cold and Compression After Rotator Cuff Repair (RCR) · NA · recruiting
NCT07226973 — Gait After THA: Direct Anterior vs Manual Posterior vs Robotic Posterior · NA · recruiting
NCT06920563 — Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education · NA · recruiting
NCT06613191 — Colonoscopy and Antiplatelet Therapy Trial · Phase 4 · not yet recruiting
NCT05516641 — Prebiotics in Rectal Cancer · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03046901 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ochsner Health System
Last refreshed: 29 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03046901.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing